BeiGene
BGNE
#968
Rank
NZ$35.44 B
Marketcap
$320.89
Share price
2.21%
Change (1 day)
15.42%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of September 2024 : NZ$4.77 Billion

According to BeiGene 's latest financial reports the company has NZ$4.77 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31NZ$5.01 B-29.72%
2022-12-31NZ$7.14 B-26.28%
2021-12-31NZ$9.68 B50.31%
2020-12-31NZ$6.44 B341.71%
2019-12-31NZ$1.45 B-45.06%
2018-12-31NZ$2.65 B125.21%
2017-12-31NZ$1.17 B121.87%
2016-12-31NZ$0.53 B262.02%
2015-12-31NZ$0.14 B159.12%
2014-12-31NZ$56.66 M1085.99%
2013-12-31NZ$4.77 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
NZ$28.95 M-99.39%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.71 B-84.96%๐Ÿ‡บ๐Ÿ‡ธ USA